NASDAQ:IDXX IDEXX Laboratories - IDXX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IDEXX Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $497.43 -10.25 (-2.02%) (As of 02/8/2023 12:00 AM ET) Add Compare Share Share Today's Range$492.97▼$504.7750-Day Range$399.93▼$507.6852-Week Range$317.06▼$560.92Volume539,491 shsAverage Volume634,540 shsMarket Capitalization$41.20 billionP/E Ratio61.95Dividend YieldN/APrice Target$514.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability IDEXX Laboratories MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside4.0% Upside$514.75 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.80Upright™ Environmental ScoreNews Sentiment0.53Based on 37 Articles This WeekInsider TradingSelling Shares$7.48 M Sold Last QuarterProj. Earnings Growth14.24%From $9.48 to $10.83 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.21 out of 5 starsMedical Sector487th out of 1,029 stocksDiagnostic Substances Industry8th out of 14 stocks 2.4 Analyst's Opinion Consensus RatingIDEXX Laboratories has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $514.75, IDEXX Laboratories has a forecasted upside of 4.0% from its current price of $495.08.Amount of Analyst CoverageIDEXX Laboratories has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IDXX. Previous Next 0.0 Dividend Strength Dividend YieldIDEXX Laboratories does not currently pay a dividend.Dividend GrowthIDEXX Laboratories does not have a long track record of dividend growth. Previous Next 2.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIDEXX Laboratories has received a 20.02% net impact score from Upright. Idexx Laboratories seems to create the most significant positive value in categories "Taxes", "Nutrition", and "Jobs". The positive contribution in the "Nutrition" impact category is mostly driven by its "Veterinary x-rays", "Veterinary hematology analyzers", and "Veterinary services for livestock" products. See details.Environmental SustainabilityThe Environmental Impact score for IDEXX Laboratories is -2.80. Previous Next 2.5 News and Social Media Coverage News SentimentIDEXX Laboratories has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 37 news articles for IDEXX Laboratories this week, compared to 5 articles on an average week.Search Interest20 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -42% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,481,338.00 in company stock.Percentage Held by InsidersOnly 2.06% of the stock of IDEXX Laboratories is held by insiders.Percentage Held by Institutions87.90% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for IDEXX Laboratories are expected to grow by 14.24% in the coming year, from $9.48 to $10.83 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEXX Laboratories is 61.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.16.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEXX Laboratories is 61.65, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 110.86.Price to Earnings Growth RatioIDEXX Laboratories has a PEG Ratio of 2.95. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIDEXX Laboratories has a P/B Ratio of 67.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IDEXX Laboratories (NASDAQ:IDXX) StockIDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in WestRead More Receive IDXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address IDXX Stock News HeadlinesFebruary 8, 2023 | finance.yahoo.comIDEXX Laboratories, Inc. (NASDAQ:IDXX) insiders made a handsome sum after selling stock worth US$508 per share at present for US$510February 8, 2023 | americanbankingnews.comIDEXX Laboratories, Inc. to Post Q1 2023 Earnings of $2.31 Per Share, William Blair Forecasts (NASDAQ:IDXX)February 8, 2023 | Vector Vest (Ad)Free Stock Analysis Report: Get Buy, Sell, or Hold RecommendationGet a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. February 7, 2023 | finance.yahoo.comIDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2022 Earnings Call TranscriptFebruary 7, 2023 | finance.yahoo.comIs AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?February 7, 2023 | americanbankingnews.comIDEXX Laboratories (NASDAQ:IDXX) Releases FY 2023 Earnings GuidanceFebruary 7, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Idexx Laboratories (IDXX), Neurocrine (NBIX) and aTyr Pharma (LIFE)February 7, 2023 | americanbankingnews.comResearch Analysts Set Expectations for IDEXX Laboratories, Inc.'s FY2023 Earnings (NASDAQ:IDXX)February 8, 2023 | Oxford Club (Ad)Dividend Expert Reveals His Biggest Income Secrets… Free of ChargeMarc Lichtenfeld –Author of the best-selling book Get Rich With Dividends – is giving away his Ultimate Dividend Package… Get His #1 Dividend Stock… The Safest 9% Dividend in the World… Top Three “Extreme Dividend” Stocks, And Much, Much MoreFebruary 6, 2023 | finance.yahoo.comAnalyst Says IDEXX Laboratories' Long-Term Growth Outlook Remains StrongFebruary 6, 2023 | msn.comIDEXX Laboratories Posts Better-Than-Expected Fourth-Quarter Results, Offers In-Line Full-Year 2023 GuidanceFebruary 6, 2023 | finanznachrichten.deIDEXX Laboratories, Inc.: IDEXX Laboratories Announces Fourth Quarter and Full Year 2022 ResultsFebruary 6, 2023 | baystreet.caIDEXX Stumbles on Q4 and Full-Year FiguresFebruary 6, 2023 | markets.businessinsider.comIDEXX Laboratories Sees Higher Earnings, Revenues In FY23 - UpdateFebruary 6, 2023 | markets.businessinsider.comIDEXX Laboratories Inc Q4 Income Climbs, Beats estimatesFebruary 6, 2023 | finance.yahoo.comIDEXX Laboratories Announces Fourth Quarter and Full Year 2022 ResultsFebruary 6, 2023 | finance.yahoo.comIdexx Laboratories (IDXX) Q4 Earnings and Revenues Beat EstimatesFebruary 6, 2023 | americanbankingnews.comIDEXX Laboratories (NASDAQ:IDXX) Updates FY23 Earnings GuidanceFebruary 5, 2023 | reuters.comIDXX.OQ - | Stock Price & Latest News | ReutersFebruary 4, 2023 | finance.yahoo.comIs It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?February 4, 2023 | americanbankingnews.comIDEXX Laboratories (IDXX) Set to Announce Quarterly Earnings on MondayFebruary 3, 2023 | msn.comA Preview Of IDEXX Laboratories's EarningsFebruary 3, 2023 | seekingalpha.comIDEXX Laboratories Q4 2022 Earnings PreviewJanuary 31, 2023 | marketwatch.comIDEXX Laboratories Inc. stock falls Tuesday, underperforms marketJanuary 31, 2023 | finance.yahoo.comSONVY or IDXX: Which Is the Better Value Stock Right Now?January 29, 2023 | americanbankingnews.comIDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives $473.13 Average PT from AnalystsJanuary 29, 2023 | americanbankingnews.comIDEXX Laboratories (NASDAQ:IDXX) Price Target Raised to $530.00 at The Goldman Sachs GroupSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IDXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address IDXX Company Calendar Last Earnings2/06/2023Today2/08/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:IDXX CUSIP45168D10 CIK874716 Webwww.idexx.com Phone(207) 556-0300Fax207-556-4346Employees10,350Year Founded1983Price Target and Rating Average Stock Price Forecast$514.75 High Stock Price Forecast$600.00 Low Stock Price Forecast$415.00 Forecasted Upside/Downside+3.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$8.03 Trailing P/E Ratio61.95 Forward P/E Ratio52.47 P/E Growth2.95Net Income$744.84 million Net Margins20.17% Pretax Margin25.54% Return on Equity124.51% Return on Assets25.66% Debt Debt-to-Equity Ratio1.14 Current Ratio0.89 Quick Ratio0.59 Sales & Book Value Annual Sales$3.37 billion Price / Sales12.23 Cash Flow$6.72 per share Price / Cash Flow74.05 Book Value$7.35 per share Price / Book67.68Miscellaneous Outstanding Shares82,820,000Free Float81,111,000Market Cap$41.20 billion OptionableOptionable Beta1.17 Social Links Key ExecutivesJonathan J. MazelskyPresident, Chief Executive Officer & DirectorBrian Patrick McKeonChief Financial Officer, Treasurer & Executive VPKen GradyChief Information Officer & Senior VPMurthy YerramilliSenior Vice President-Research & DevelopmentMartin Alexander SmithChief Technology Officer & Executive VPKey CompetitorsDexComNASDAQ:DXCMBiogenNASDAQ:BIIBCenteneNYSE:CNCAlconNYSE:ALCHaleonNYSE:HLNView All CompetitorsInsiders & InstitutionsGlenview Trust CoBought 58 shares on 2/8/2023Ownership: 0.010%Dakota Wealth ManagementBought 68 shares on 2/8/2023Ownership: 0.002%InterOcean Capital Group LLCBought 40 shares on 2/8/2023Ownership: 0.002%Main Street Financial Solutions LLCSold 49 shares on 2/8/2023Ownership: 0.001%Belpointe Asset Management LLCSold 36 shares on 2/8/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions IDXX Stock - Frequently Asked Questions Should I buy or sell IDEXX Laboratories stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDXX shares. View IDXX analyst ratings or view top-rated stocks. What is IDEXX Laboratories' stock price forecast for 2023? 8 brokerages have issued 1-year price objectives for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $415.00 to $600.00. On average, they expect the company's share price to reach $514.75 in the next year. This suggests a possible upside of 2.4% from the stock's current price. View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts. How have IDXX shares performed in 2023? IDEXX Laboratories' stock was trading at $407.96 at the beginning of 2023. Since then, IDXX shares have increased by 23.3% and is now trading at $502.92. View the best growth stocks for 2023 here. When is IDEXX Laboratories' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our IDXX earnings forecast. How were IDEXX Laboratories' earnings last quarter? IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its quarterly earnings data on Monday, February, 6th. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.92 by $0.13. The business earned $828.60 million during the quarter, compared to analysts' expectations of $820.91 million. IDEXX Laboratories had a net margin of 20.17% and a trailing twelve-month return on equity of 124.51%. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.89 EPS. Read the conference call transcript. What guidance has IDEXX Laboratories issued on next quarter's earnings? IDEXX Laboratories updated its FY 2023 earnings guidance on Monday, February, 6th. The company provided earnings per share guidance of $9.27-$9.75 for the period, compared to the consensus earnings per share estimate of $9.50. The company issued revenue guidance of $3.59 billion-$3.69 billion, compared to the consensus revenue estimate of $3.62 billion. What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO? 40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees. What other stocks do shareholders of IDEXX Laboratories own? Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP). What is IDEXX Laboratories' stock symbol? IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX." Who are IDEXX Laboratories' major shareholders? IDEXX Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Swiss National Bank (0.41%), LGT Capital Partners LTD. (0.38%), UMB Bank n.a. (0.34%), Robeco Institutional Asset Management B.V. (0.31%), Sumitomo Mitsui Trust Holdings Inc. (0.30%) and Manning & Napier Group LLC (0.21%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek. View institutional ownership trends. How do I buy shares of IDEXX Laboratories? Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IDEXX Laboratories' stock price today? One share of IDXX stock can currently be purchased for approximately $502.92. How much money does IDEXX Laboratories make? IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $41.65 billion and generates $3.37 billion in revenue each year. The company earns $744.84 million in net income (profit) each year or $8.03 on an earnings per share basis. How many employees does IDEXX Laboratories have? The company employs 10,350 workers across the globe. How can I contact IDEXX Laboratories? IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346. This page (NASDAQ:IDXX) was last updated on 2/8/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.